healthcare

PTC Therapeutics Wins Big With Agilis Biotherapeutics Acquisition

PTC Therapeutics Inc. (NASDAQ: PTCT) shares made a handy gain on Friday after the firm announced that it would be acquiring Agilis Biotherapeutics. The transaction was approved by the boards ...
Read Full Story »

Mersana Cries for Mercy

Mersana Therapeutics Inc. (NASDAQ: MRSN) shares took a massive dive on Thursday morning and were actually halted before markets opened. This came after the company announced that the U.S. Food ...
Read Full Story »

Rubius Therapeutics Enters the Market With a Bang

Rubius Therapeutics Inc. (NASDAQ: RUBY) entered the market with a bang in its initial public offering (IPO). The stock entered the market just over $30 per share, well above its ...
Read Full Story »

Pfizer and Eli Lilly Win in Late-Stage Osteoarthitis Study

Pfizer Inc. (NYSE: PFE) and Eli Lilly and Co. (NYSE: LLY) shares were largely unaffected after the firms announced results from a joint late-stage trial in patients with osteoarthritis (OA) ...
Read Full Story »

Why Voyager Therapeutics Shares Are Surging

Voyager Therapeutics Inc. (NASDAQ: VYGR) shares saw a handy gain on Tuesday after the company announced that it received some feedback from the U.S. Food and Drug Administration (FDA) from ...
Read Full Story »

Why UnitedHealth Earnings Aren’t Enough

UnitedHealth Group Inc. (NYSE: UNH) released its second-quarter financial results before the markets opened on Tuesday. The company said that it had $3.14 in earnings per share (EPS) and $56.1 ...
Read Full Story »

Are Johnson & Johnson Q2 Earnings Good Enough?

Johnson & Johnson (NYSE: JNJ) reported its second-quarter financial results before the markets opened on Tuesday. The health care giant said that it had $2.10 in earnings per share (EPS) ...
Read Full Story »

What to Watch For in UnitedHealth Earnings

UnitedHealth Group Inc. (NYSE: UNH) is scheduled to report its second-quarter financial results before the markets open on Tuesday. Thomson Reuters consensus estimates call for $3.04 in earnings per share ...
Read Full Story »

What to Expect When Johnson & Johnson Reports Tuesday Morning

Johnson & Johnson (NYSE: JNJ) is set to report its second-quarter financial results before the markets open on Tuesday. The consensus estimates from Thomson Reuters are $2.07 in earnings per ...
Read Full Story »

Why Tonix Pharmaceuticals Is Winning Big on Monday

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) saw its shares make a solid gain to start off the week after the company announced an update from the U.S. Food and Drug ...
Read Full Story »

Will Acceleron Pharma Momentum Continue After New FDA Nod?

Acceleron Pharma Inc. (NASDAQ: XLRN) shares reached a multiyear high last month after the company and Celgene Corp. (NASDAQ: CELG) announced positive late-stage trial results, but those shares dipped on Friday ...
Read Full Story »

How Zogenix Is Winning Big With Late-Stage Seizure Study

Zogenix Inc. (NASDAQ: ZGNX) shares made a solid gain on Thursday after the company announced positive results from its late-stage seizure trial. Essentially, the company reported positive top-line results from ...
Read Full Story »

Where Did Major Pharma Short Sellers Go?

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Short Sellers Back Off Major Biotechs

The short interest data are out for the most recent settlement date, June 29. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, ...
Read Full Story »

Akcea Therapeutics Jumps on European Marketing Approval

Akcea Therapeutics Inc. (NASDAQ: AKCA) shares saw a nice bump on Wednesday after the company announced in conjunction with Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) that they had received a marketing ...
Read Full Story »